{"product_id":"akya-vrio-analysis","title":"Akoya Biosciences, Inc. (AKYA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Akoya Biosciences, Inc. (AKYA) truly built to last? This concise VRIO analysis cuts straight to the chase, evaluating whether its core assets possess the necessary Value, Rarity, Inimitability, and Organization to secure a sustainable competitive edge. Dive in now to see the distilled summary of its true market power and strategic implications.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Proprietary Spatial Phenotyping Platform (PhenoCycler\/PhenoImager)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a core asset for Akoya Biosciences, Inc., their spatial phenotyping platform. Honestly, this isn't just another lab instrument; it’s the engine driving their whole business model. The takeaway here is that the combination of high-plex biomarker analysis with whole-slide context is what sets them apart right now, giving them a strong, though not entirely unassailable, competitive edge.\u003c\/p\u003e\n\n\u003ch\u003eValue: Enables single-cell resolution mapping of biomarkers across whole tissue, which is crucial for understanding disease context.\u003c\/h\u003e\n\u003cp\u003eThis platform delivers the 'where' along with the 'what' in cellular analysis. By mapping biomarkers at single-cell resolution across an entire tissue section, researchers get a computable map of the tumor microenvironment or other complex tissues. This capability is defintely crucial for identifying spatial phenotypic signatures - new biomarkers that predict things like immunotherapy response, which is a huge area of focus in oncology right now. The ability to visualize cell-to-cell interactions at this level is what makes the data actionable for drug development.\u003c\/p\u003e\n\n\u003ch\u003eRarity: The specific integration of high-plex capability with whole-slide imaging is relatively rare in the market.\u003c\/h\u003e\n\u003cp\u003eWhile spatial biology is heating up, Akoya Biosciences has managed to carve out a niche by integrating high-plex (many biomarkers) with whole-slide imaging in a streamlined way. They are actively expanding this, for example, with the PhenoCode Discovery IO60 panel, which supports this high-plex analysis. The fact that their technology is being selected for landmark studies, like the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, suggests that the market sees this specific combination as unique or superior for certain large-scale needs.\u003c\/p\u003e\n\n\u003ch\u003eImitability: High; the underlying patented optics and fluidics technology present significant barriers to easy replication.\u003c\/h\u003e\n\u003cp\u003eReplicating this technology isn't a weekend project. The barriers to imitation are rooted in protected intellectual property - their patents covering the optics and fluidics are key here. Furthermore, the continuous improvement cycle, like the 2.0 upgrades, shows they are investing to stay ahead. For instance, the PhenoCycler-Fusion 2.0 system allows customers to process twice as many samples per week, and the PhenoImager 2.0 platform offers a 5x workflow improvement. Building that entire integrated system, from hardware to proprietary software and validated content, is a massive undertaking for a competitor.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on their installed base growth, which speaks to market adoption of this complex tech:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue as of Q1 2025 (Mar 31, 2025)\u003c\/th\u003e\n\u003cth\u003ePrior Year Period (Q1 2024 Est.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Instrument Installed Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,359\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,213\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoCyclers (Installed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e410\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e354\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoImagers (Installed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e949\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e859\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Citing Publications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,891\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1,307\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the capital expenditure required to build out a competing manufacturing center of excellence, which Akoya launched to improve gross margins.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: The company offers a full continuum of solutions, from discovery to clinical research, showing organized exploitation of the tech.\u003c\/h\u003e\n\u003cp\u003eAkoya Biosciences isn't just selling a box; they are organized to support the entire research lifecycle. This organized exploitation of their core tech means they capture revenue across different stages of customer maturity. They have a clear product continuum: PhenoCode Panels, PhenoCycler, PhenoImager Fusion, and PhenoImager HT Instruments. This structure helps them move from basic discovery work into more regulated translational and clinical research settings.\u003c\/p\u003e\n\u003cp\u003eTheir organizational focus in early 2025 included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFocusing on operational discipline.\u003c\/li\u003e\n\u003cli\u003eIncreasing the installed base despite funding uncertainty.\u003c\/li\u003e\n\u003cli\u003eExpanding content into neurobiology.\u003c\/li\u003e\n\u003cli\u003eAchieving a Q1 2025 gross margin of \u003cstrong\u003e59.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained, grounded in protected intellectual property and a fully integrated system.\u003c\/h\u003e\n\u003cp\u003eThe combination of proprietary, hard-to-replicate technology (Imitability) and a comprehensive, end-to-end workflow that serves the entire research continuum (Organization) points toward a \u003cstrong\u003esustained competitive advantage\u003c\/strong\u003e, at least for the near term. Their Q1 2025 revenue was $16.6 million, showing they are successfully monetizing this advantage, even if the TTM revenue of $79.96 Million USD shows a slight dip from the prior year. The IP acts as a moat, and the integrated system creates high switching costs for researchers who have built their pipelines around the platform.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: High-Plex Reagent Portfolio (e.g., PhenoCode IO60 Panel)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows deep profiling of targets, accelerating biomarker discovery, especially in oncology and new areas like neurobiology.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePanel\/Assay Feature\u003c\/th\u003e\n\u003cth\u003eSpecification\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoCode Discovery IO60 Panel Markers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60\u003c\/strong\u003e tumor and immunology markers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmune Cell Coverage (IO60)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e of major immune cell types\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmune Checkpoint Coverage (IO60)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e85%\u003c\/strong\u003e of key immune checkpoints\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew ADC Breast Cancer Assay Targets\u003c\/td\u003e\n\u003ctd\u003eHER2, TROP2, Ki-67, ER\/PR, proprietary membrane-localization cocktail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Ultrahigh-plex spatial proteomics panels are rare; the IO60 is cited as a transformative tool.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate to High; developing such complex, validated panels requires substantial R\u0026amp;D and manufacturing expertise.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The strategic roadmap shows organized expansion into new verticals, leveraging the success of existing panels.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInstrument installed base as of March 31, 2025: \u003cstrong\u003e1,359\u003c\/strong\u003e (410 PhenoCyclers, 949 PhenoImagers)\u003c\/li\u003e\n\u003cli\u003eInstrument installed base as of December 31, 2024: \u003cstrong\u003e1,330\u003c\/strong\u003e (400 PhenoCyclers, 930 PhenoImagers)\u003c\/li\u003e\n\u003cli\u003eTotal publications citing Akoya's technology as of March 31, 2025: \u003cstrong\u003e1,891\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal publications citing Akoya's technology as of December 31, 2024: \u003cstrong\u003e1,733\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eReagents and services revenue continued to increase in Q1 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary to Sustained, depending on the speed of next-generation panel development.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (Period Ending March 31, 2025)\u003c\/th\u003e\n\u003cth\u003eAmount\/Percentage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin (Q1 2025 GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (Q1 2025 GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss (Q1 2025 GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash used in operating activities (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003ePhenoCode IO60 Panel paired with PhenoCycler-Fusion 2.0 enables processing of over \u003cstrong\u003e16 samples per week\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Instrument Installed Base \u0026amp; Recurring Potential\n\u003c\/h2\u003e\n\u003cp\u003eThe instrument installed base serves as the foundation for generating recurring revenue streams through the sale of consumables, reagents, and services, while simultaneously establishing customer lock-in within the spatial biology ecosystem. The total installed base reached \u003cstrong\u003e1,359\u003c\/strong\u003e instruments as of March 31, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The installed base directly underpins the potential for recurring consumable\/reagent revenue, which is critical for long-term financial stability and customer retention. The growth in publications citing Akoya's technology further validates the installed base's utility and drives demand for associated reagents and services. The total number of publications citing Akoya's technology reached \u003cstrong\u003e1,891\u003c\/strong\u003e as of March 31, 2025, representing a \u003cstrong\u003e44.7%\u003c\/strong\u003e year-over-year increase.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While competitors possess installed bases, Akoya's represents a specific level of market penetration within the spatial biology segment, particularly with its PhenoCycler and PhenoImager platforms. The installed base is a tangible measure of market adoption in a rapidly evolving field.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Imitability is constrained by the significant capital investment required by customers to acquire the instrumentation, which translates into high switching costs once workflows and data pipelines are established on the platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective deployment and sales execution are evidenced by the \u003cstrong\u003e12.0%\u003c\/strong\u003e year-over-year growth in the installed base, which increased from \u003cstrong\u003e1,213\u003c\/strong\u003e instruments as of March 31, 2024, to \u003cstrong\u003e1,359\u003c\/strong\u003e as of March 31, 2025. The company's operational discipline in Q1 2025, which included a gross margin of \u003cstrong\u003e59.3%\u003c\/strong\u003e and a reduction in operating expenses by \u003cstrong\u003e22.3%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$23.3 million\u003c\/strong\u003e, supports the organization's ability to manage and grow this asset base despite macroeconomic pressures.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The current competitive advantage derived from this asset is viewed as temporary, primarily because the value of the installed base is being actively realized through the terms of the pending acquisition by Quanterix Corporation.\u003c\/p\u003e\n\n\u003cp\u003eThe following table details the instrument base evolution and associated publication traction:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 (As of Mar 31, 2025)\u003c\/td\u003e\n\u003ctd\u003eQ1 2024 (As of Mar 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Instrument Installed Base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,359\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,213\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoCyclers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e410\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e354\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoImagers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e949\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e859\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Publications Citing Technology\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,891\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,307\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAdditional relevant financial and operational data from the period ending March 31, 2025, includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 Revenue: \u003cstrong\u003e$16.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Operating Loss: Improved by \u003cstrong\u003e37.9%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$13.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, Cash Equivalents and Marketable Securities: \u003cstrong\u003e$27.5 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eCurrent Portion of Long-Term Debt: Reclassified to \u003cstrong\u003e$76.5 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Advanced Biopharma Services (ABS) \u0026amp; CLIA Capability\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAccelerates the translational and clinical path for biopharma partners via custom assays and CLIA-certified lab work. The Advanced Biopharma Services (ABS) now offers a new multiplex immunofluorescence (mIF) assay for Antibody-Drug Conjugate (ADC) breast cancer development, which includes simultaneous quantification of targets such as \u003cstrong\u003eHER2\u003c\/strong\u003e, \u003cstrong\u003eTROP2\u003c\/strong\u003e, \u003cstrong\u003eKi-67\u003c\/strong\u003e, and \u003cstrong\u003eER\/PR\u003c\/strong\u003e with proprietary membrane-localization cocktails. The ABS capability is anchored in a \u003cstrong\u003eCLIA-certified laboratory\u003c\/strong\u003e for clinical-grade assay development.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eRare for a tools company to have an integrated, CLIA-certified service arm specifically for spatial assays. The ABS laboratory achieved \u003cstrong\u003eCLIA certification\u003c\/strong\u003e, enabling support for later-stage clinical trial studies with biopharmaceutical partners.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh; establishing a CLIA-certified lab and specialized service workflows is a time-consuming regulatory hurdle. The company secured its \u003cstrong\u003eCLIA Certificate of Registration\u003c\/strong\u003e following receipt of a Massachusetts Department of Public Health clinical laboratory license, a milestone achieved around \u003cstrong\u003eNovember 2021\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe expansion of ABS, including a new ADC breast cancer assay, shows organized service delivery. The service includes comprehensive support from assay customization to tissue staining, high-resolution imaging, image analysis, and reporting. The company's overall technology adoption is evidenced by:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eTotal publications citing Akoya's technology reaching \u003cstrong\u003e1,891\u003c\/strong\u003e as of Q1 2025, a year-over-year increase of \u003cstrong\u003e44.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eInstrument installed base of \u003cstrong\u003e1,359\u003c\/strong\u003e systems as of Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\nThe recent launch of the ADC panel demonstrates organized integration of new assay development into the service offering.\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained, due to the high barrier of regulatory compliance and service integration. The integration of the \u003cstrong\u003eCLIA-certified lab\u003c\/strong\u003e with proprietary spatial imaging and analysis workflows creates a significant barrier to entry for competitors focused solely on instrumentation. The ABS program aims to support partners from translational discovery through to \u003cstrong\u003eIVD\u003c\/strong\u003e development.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue \/ Period\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $18.4 million in Q1 2024 (a \u003cstrong\u003e9.8%\u003c\/strong\u003e decrease).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to 45.7% in Q1 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Instrument Installed Base (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,359\u003c\/strong\u003e units\u003c\/td\u003e\n\u003ctd\u003eIncludes \u003cstrong\u003e410 PhenoCyclers\u003c\/strong\u003e and \u003cstrong\u003e949 PhenoImagers\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLIA Certification Milestone\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnables support for later-stage clinical trial studies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew ADC Assay Components\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eHER2, TROP2, Ki-67, ER\/PR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncluded in the new multiplex immunofluorescence panel offered via ABS.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Publication Footprint \u0026amp; Key Opinion Leader (KOL) Endorsement\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Builds essential scientific credibility and validates the technology's utility in high-impact research. Total publications cited reached \u003cstrong\u003e1,891\u003c\/strong\u003e by Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; the \u003cstrong\u003e44.7%\u003c\/strong\u003e year-over-year growth in publications is significant, non-transferable validation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is an emergent asset built over time through scientific adoption.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company actively showcases KOL quotes and customer data, demonstrating effective communication of scientific impact.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; scientific reputation is a long-term asset that is difficult for newcomers to replicate.\u003c\/p\u003e\n\u003cp\u003eThe expanding publication footprint demonstrates increasing scientific validation across key research areas:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe technology was the central spatial biology solution used for the discovery of key proteins and cell types in atlases of the human intestine and breast.\u003c\/li\u003e\n\u003cli\u003eThe company launched the largest commercially available single-cell spatial proteomics atlas in partnership with Enable Medicine at the AACR Annual Meeting (April 25–30, Chicago, IL).\u003c\/li\u003e\n\u003cli\u003eThe installed base of instruments, which underpins publication volume, grew to \u003cstrong\u003e1,359\u003c\/strong\u003e as of March 31, 2025, a year-over-year increase of \u003cstrong\u003e12.0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePublication Citation Growth Trajectory:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eReporting Period End Date\u003c\/td\u003e\n\u003ctd\u003eTotal Publications Citing Technology\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Publication Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 31, 2025 (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,891\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 31, 2024 (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,733\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e49.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeptember 30, 2024 (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,578\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 30, 2024 (Q2 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,450\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 31, 2024 (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,307\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Strategic CRO\/Partner Network (e.g., BostonGene, Precision for Medicine)\n\u003c\/h2\u003e\n\u003cp\u003eThe Strategic CRO\/Partner Network, which includes entities such as \u003cstrong\u003ePrecision for Medicine\u003c\/strong\u003e and \u003cstrong\u003eBostonGene\u003c\/strong\u003e, is leveraged to embed Akoya's spatial biology technology, including the \u003cstrong\u003ePhenoCode™ Discovery IO60 panel\u003c\/strong\u003e, into established service offerings.\u003c\/p\u003e\n\u003cp\u003eThe scale of the underlying technology ecosystem that these partners utilize includes an instrument installed base of \u003cstrong\u003e1,213\u003c\/strong\u003e as of Q1 2024. Furthermore, the technology's scientific validation is evidenced by a total of \u003cstrong\u003e1,307\u003c\/strong\u003e publications citing Akoya's technology as of March 31, 2024.\u003c\/p\u003e\n\u003cp\u003eThe company's overall financial performance context includes a Q1 2024 revenue of \u003cstrong\u003e$18.4 million\u003c\/strong\u003e and a full-year 2024 revenue guidance range of \u003cstrong\u003e$104.0-$112.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe VRIO assessment for this network is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDrives market adoption of high-value panels like IO60 by embedding the technology into established service offerings.\u003c\/td\u003e\n\u003ctd\u003eThe IO60 panel is the flagship ultrahigh-plex immuno-oncology solution. Partnerships make advanced spatial proteomics accessible to all researchers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate; deep, integrated partnerships that drive core product adoption are less common than simple collaborations.\u003c\/td\u003e\n\u003ctd\u003ePartners like BostonGene integrate Akoya's solutions with their AI-powered multiomics platform for end-to-end imaging solutions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate; requires sustained relationship building and technical integration with external service providers.\u003c\/td\u003e\n\u003ctd\u003eThe integration involves leveraging Akoya's high-throughput automated multiplex immunofluorescence platforms.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePartnerships are actively used to expand reach into new research verticals, showing organized ecosystem development.\u003c\/td\u003e\n\u003ctd\u003eThe strategy aims to expand reach beyond oncology into verticals like neurobiology. The network of qualified CRO service providers is established.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe resulting Competitive Advantage is assessed as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as partner relationships can shift, though deep integration offers some stickiness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Spatial Biology 2.0 Speed\/Throughput Innovations\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Addresses key market limitations (speed, throughput) with features like high-speed whole-slide imaging and multi-slide automation.\u003c\/p\u003e\n\u003cp\u003eThe PhenoImager® HT 2.0 platform can generate whole slide scans of up to 7 colors in less than 12 minutes for a 15mm x 15mm region. Enhancements to the PhenoCycler®-Fusion 2.0 System allow customers to process twice as many samples per week. The PhenoImager HT 2.0 delivers a 5x workflow improvement by enabling rapid real-time image analysis directly on the HT instrument.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; claims of 'unprecedented speed' suggest a technical lead over legacy spatial platforms.\u003c\/p\u003e\n\u003cp\u003eThe PhenoCycler-Fusion 2.0 is positioned as the highest throughput spatial discovery platform on the market. The system can image 1 million cells in 10 minutes with accelerated parallel imaging and fluidics. As of Q1 2025, the company's total instrument installed base was 1,359 units.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires continuous, focused R\u0026amp;D investment in optics and fluidics to maintain the lead.\u003c\/p\u003e\n\u003cp\u003eThe company has actively launched platform upgrades, such as PhenoCycler®-Fusion 2.0 and PhenoImager® HT 2.0, indicating ongoing R\u0026amp;D investment. The company reported $16.6 million in revenue for Q1 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The product roadmap is clearly structured around delivering these speed and scale improvements for users.\u003c\/p\u003e\n\u003cp\u003eThe launch of the 2.0 Platforms provides customers with immediate benefits in throughput expansion. Total publications citing Akoya's technology reached 1,891 as of Q1 2025, a year-over-year increase of 44.7% compared to 1,307 in the prior year period. Gross margin for Q1 2025 was 59.3%.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as competitors will inevitably focus on closing the speed gap metric by metric.\u003c\/p\u003e\n\n\u003cp\u003eKey Speed and Throughput Metrics for 2.0 Platforms:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePerformance Figure\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoImager HT 2.0\u003c\/td\u003e\n\u003ctd\u003eWhole Slide Scan Time (7 Colors)\u003c\/td\u003e\n\u003ctd\u003eLess than 12 minutes (15mm x 15mm region)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoImager HT 2.0\u003c\/td\u003e\n\u003ctd\u003eWorkflow Improvement\u003c\/td\u003e\n\u003ctd\u003e5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoImager HT 2.0\u003c\/td\u003e\n\u003ctd\u003eWalk-Away Automation Throughput\u003c\/td\u003e\n\u003ctd\u003e400+ slides\/week\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoCycler-Fusion 2.0\u003c\/td\u003e\n\u003ctd\u003eSample Throughput Increase\u003c\/td\u003e\n\u003ctd\u003eTwice as many samples per week\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhenoCycler-Fusion 2.0\u003c\/td\u003e\n\u003ctd\u003eCell Imaging Speed\u003c\/td\u003e\n\u003ctd\u003eImage 1 million cells in 10 minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Market Positioning as 'The Spatial Biology Company®'\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The positioning supports the company's offering of comprehensive single-cell imaging solutions for spatial phenotyping. Financial performance metrics reflect the scale of operations within this positioning. Full Year 2024 revenue was reported as \u003cstrong\u003e$81.67 million\u003c\/strong\u003e. Revenue for the first quarter of 2025 was \u003cstrong\u003e$16.6 million\u003c\/strong\u003e, with a Gross Margin of \u003cstrong\u003e59.3%\u003c\/strong\u003e in Q1 2025. In 2022, Akoya Biosciences was estimated to hold a share of the spatial biology market, which was valued at approximately \u003cstrong\u003e$320M\u003c\/strong\u003e, alongside 10X Genomics and NanoString, with the top vendors comprising approximately \u003cstrong\u003e50%\u003c\/strong\u003e of that market.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While competitors exist in the spatial biology sector, the canonical branding as 'The Spatial Biology Company®' is unique. The company's technology adoption, measured by publications and installed base, demonstrates market penetration supporting the claim of category leadership.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The phrase 'The Spatial Biology Company' is a \u003cstrong\u003eregistered trademark\u003c\/strong\u003e of Akoya Biosciences, Inc., which creates a legal barrier to direct imitation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Demonstrated by consistent official use and quantifiable growth metrics across key operational areas, indicating the positioning is integrated into the corporate strategy.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDate\/Period End\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Publications Citing Technology\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,891\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Publications Citing Technology\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,578\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument Installed Base\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,359\u003c\/strong\u003e instruments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstrument Installed Base\u003c\/td\u003e\n\u003ctd\u003eQ4 2023\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e1,200\u003c\/strong\u003e instruments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe consistent use of the tagline is evidenced across official financial announcements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 2025 press release explicitly identifies the company as 'Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), \u003cstrong\u003eThe Spatial Biology Company®\u003c\/strong\u003e'.\u003c\/li\u003e\n\u003cli\u003eQ4 2023 press release identified the company as 'Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), \u003cstrong\u003eThe Spatial Biology Company®\u003c\/strong\u003e'.\u003c\/li\u003e\n\u003cli\u003eThe company's mission statement, as of 2021, included the phrase 'As \u003cstrong\u003eThe Spatial Biology Company®\u003c\/strong\u003e, Akoya Biosciences' mission is to bring context to the world of biology...'.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the combination of a \u003cstrong\u003eregistered trademark\u003c\/strong\u003e and demonstrated market traction, evidenced by an installed base growth to \u003cstrong\u003e1,359\u003c\/strong\u003e instruments by Q1 2025 and publication volume reaching \u003cstrong\u003e1,891\u003c\/strong\u003e, establishes brand equity that is difficult for competitors to replicate quickly.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkoya Biosciences, Inc. (AKYA) - VRIO Analysis: Organizational Focus on Operational Discipline \u0026amp; Margin Improvement\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImproved financial health, evidenced by a Q1 2025 gross margin of \u003cstrong\u003e59.3%\u003c\/strong\u003e and a \u003cstrong\u003e37.9%\u003c\/strong\u003e reduction in operating loss. The operating loss for Q1 2025 was \u003cstrong\u003e$13.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$21.6 million\u003c\/strong\u003e in the prior year period. Revenue for Q1 2025 was \u003cstrong\u003e$16.6 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e9.8%\u003c\/strong\u003e year-over-year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; many life science tools companies struggle with consistent margin and expense control. The gross margin improvement to \u003cstrong\u003e59.3%\u003c\/strong\u003e from \u003cstrong\u003e45.7%\u003c\/strong\u003e year-over-year demonstrates a deviation from common industry struggles in margin consistency.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow; this reflects internal cultural and process achievements within the organization, such as manufacturing and cost actions mentioned as drivers for margin expansion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrated by the \u003cstrong\u003e22.3%\u003c\/strong\u003e reduction in operating expenses to \u003cstrong\u003e$23.3 million\u003c\/strong\u003e in Q1 2025, showing effective cost management. Net cash used in operating activities decreased by \u003cstrong\u003e$13.6 million\u003c\/strong\u003e to \u003cstrong\u003e$7.2 million\u003c\/strong\u003e in Q1 2025, compared to \u003cstrong\u003e$20.8 million\u003c\/strong\u003e in the prior year period. The company ended the quarter with \u003cstrong\u003e$27.5 million\u003c\/strong\u003e of cash, cash equivalents and marketable securities as of March 31, 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025 Value\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e59.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from 45.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown \u003cstrong\u003e22.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImproved by \u003cstrong\u003e37.9%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDown \u003cstrong\u003e9.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; financial discipline can be eroded by shifting priorities, definitely something to watch. Operational discipline is evidenced by platform adoption metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInstalled base grew to \u003cstrong\u003e1,359\u003c\/strong\u003e instruments, a \u003cstrong\u003e12.0%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003ePublications citing Akoya's technology increased to \u003cstrong\u003e1,891\u003c\/strong\u003e, demonstrating a \u003cstrong\u003e44.7%\u003c\/strong\u003e year-over-year growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516108890261,"sku":"akya-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/akya-vrio-analysis.png?v=1740143309","url":"https:\/\/dcf-model.com\/fr\/products\/akya-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}